Micafungin Accord (Micafungin)

Micafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis, and it is indicated for several serious Candida infections.

• Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections in immunocompromised patients.
• Esophageal candidiasis: eradicates Candida infection of the esophagus, relieving pain and dysphagia.
• Prophylaxis in hematopoietic stem cell transplant recipients: prevents Candida infection during periods of neutropenia.
• Candida peritonitis and intra‑abdominal infections: manages Candida‑related peritoneal and abdominal infections.

These indications are supported by clinical studies and regulatory approvals in the EU.

• Micafungin exerts its antifungal activity by selectively inhibiting the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for the synthesis of β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. Inhibition leads to weakened cell wall integrity, osmotic instability and ultimately fungal cell death, while human cells lacking this pathway are unaffected. The drug displays concentration‑dependent fungicidal activity against most Candida species and shows activity against Aspergillus spp. in vitro.

Micafungin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Infusion-related reactions: flushing, rash, or pruritus occurring during or shortly after the IV infusion.
• Fever: transient temperature rise, usually mild and self‑limiting.
• Elevated liver enzymes: mild increases in ALT and AST that typically resolve after therapy.
• Nausea: mild to moderate nausea without vomiting.

Serious or Rare Side Effects

• Severe hepatic dysfunction: hepatitis or liver failure requiring discontinuation.
• Anaphylaxis: severe hypersensitivity reaction with respiratory compromise, hypotension, and possible shock.
• Renal failure: acute kidney injury manifested by rising creatinine levels.

When using Micafungin, clinicians should observe several precautionary measures to minimize risk and ensure optimal therapy.

• Liver function monitoring: assess baseline ALT/AST and repeat during treatment.
• Renal function assessment: evaluate serum creatinine before initiation and periodically.
• Concomitant hepatotoxic drugs: avoid or use with caution when combined with other agents that affect liver.
• Immunocompromised patients: monitor closely for breakthrough fungal infections.
• Known hypersensitivity: do not administer to patients with documented allergy to micafungin or other echinocandins.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Cyclosporine: micafungin increases cyclosporine exposure, raising risk of nephrotoxicity.
• Tacrolimus: co‑administration may elevate tacrolimus levels, requiring dose adjustment.
• Sirolimus: combined use can lead to increased sirolimus concentrations and toxicity.

Moderate Interactions (Monitor Closely)

• Rifampin: strong enzyme inducer that can reduce micafungin plasma concentrations.
• Fluconazole: may increase micafungin levels, necessitating monitoring for adverse effects.
• Warfarin: potential alteration of INR; monitor coagulation parameters.